Abstract | OBJECTIVE: METHODS: Finally, a total of 8357 AMI patients with current smoking underwent successful PCI with new-generation DES (ZES, EES, and BES) were enrolled and divided into three groups as ZES (n = 3199), EES (n = 3987), and BES group (n = 1171). The primary endpoint was the occurrence of major adverse cardiac events ( MACE) defined as all-cause death (cardiac death [CD] or non- cardiac death), recurrent AMI (re-MI), any revascularization (target lesion revascularization [TLR], target vessel revascularization [TVR], and non-TVR). The secondary endpoint was the incidence of definite or probable stent thrombosis (ST). RESULTS: The 2-year adjusted hazard ratio (HR) of MACE for ZES vs. EES (1.055; 95% confidence interval [CI], 0.843-1.321; p = 0.638), ZES vs. BES (HR, 0.885; 95% CI, 0.626-1.251; p = 0.488), EES vs. BES (HR, 0.889; 95% CI, 0.633-1.250; p = 0.499), and ZES/EES vs. BES (HR, 0.891; 95% CI, 0.648-1.126; p = 0.480) were similar. The occurrence of ST after adjustment were also comparable. In addition, the 2-year adjusted HR for all-cause death, CD, re-MI, TLR, TVR, and non-TVR were not different. CONCLUSIONS: In this study, DP-DES and BP-DES showed comparable safety and efficacy during 2-year follow-up periods. Therefore, DP-DES or BP-DES are equally acceptable in AMI patients with current smoking undergoing PCI.
|
Authors | Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Dong-Ho Shin, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang |
Journal | PloS one
(PLoS One)
Vol. 13
Issue 10
Pg. e0205046
( 2018)
ISSN: 1932-6203 [Electronic] United States |
PMID | 30289945
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Polymers
- Everolimus
- zotarolimus
- Sirolimus
|
Topics |
- Drug-Eluting Stents
- Everolimus
(chemistry, pharmacology)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(surgery)
- Percutaneous Coronary Intervention
(adverse effects)
- Polymers
(chemistry, metabolism)
- Sirolimus
(analogs & derivatives, chemistry, pharmacology)
- Smoking
(adverse effects)
- Thrombosis
(etiology, prevention & control)
|